Mattel (MAT) FDA Approvals

Mattel's Drug in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by Mattel (MAT). Over the past two years, Mattel has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Barbie. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.

Barbie FDA Regulatory Events

Barbie is a drug developed by Mattel for the following indication: type 1 diabetes (T1D). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Provided Update - August 6,2025

• Drug: Barbie
• Announced Date: August 6, 2025
• Indication: type 1 diabetes (T1D)

Mattel, Inc announced a partnership between its iconic Barbie™ brand and Quo Beauty®, the beloved and multi-award-winning Canadian beauty brand developed by Shoppers Drug Mart®. Available, August 11 nationwide, the all-new line includes colour cosmetics, cosmetic accessories, and hair accessories, all inspired by the Barbie™ brand's notable impact on beauty.

On August 11, Mattel, Inc. will launch a first-ever collaboration between its iconic Barbie™ brand and Quo Beauty®, the award-winning Canadian beauty line from Shoppers Drug Mart®. This nationwide release features a 23-piece collection of colour cosmetics, hair and cosmetic accessories, and more, all inspired by Barbie’s legacy of style and self-expression.

Jennifer Gileno, Director of Licensing at Mattel Canada, says the partnership “celebrates our continued efforts to inspire the next generation to feel confident through self-expression.” Jenifer Gerlach Martin, Senior Director at Quo Beauty®, adds that the collaboration is “a milestone” reflecting shared values of confidence, playfulness, and inclusivity.

The range includes hair sets with bow headbands and scrunchies, a mini curling iron kit, peptide lip tints in Iced Mocha and Watermelon, fast-dry nail enamels, blending sponges, bath and self-care sets, and a hard cosmetic case. Fans can find the collection exclusively at Shoppers Drug Mart®, Pharmaprix®, select Loblaw Real Canadian Superstores, and online.

Provided Update - July 8,2025

• Drug: Barbie
• Announced Date: July 8, 2025
• Indication: type 1 diabetes (T1D)

Mattel, Inc announced that Barbie® is debuting the first Barbie doll with type 1 diabetes (T1D).

Mattel, Inc. announced that Barbie® is debuting the first-ever Barbie doll with type 1 diabetes (T1D). Created in partnership with Breakthrough T1D, the doll is part of the global Fashionistas lineup and is designed to represent children living with T1D. The doll features realistic details such as a continuous glucose monitor on her arm, held in place by heart-shaped, Barbie pink medical tape, and an insulin pump attached to her waist. Her stylish blue polka dot outfit and matching accessories are nods to diabetes awareness, helping to foster inclusion and empathy through imaginative play.

This pioneering doll allows more children to see themselves reflected in Barbie, empowering those with T1D by showing that life with the condition can be vibrant and full of possibilities. Barbie’s debut T1D doll highlights the brand’s ongoing commitment to representation and inclusivity.